Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Project BioShield”: Industry Has Concerns, FDA Offers Support

Executive Summary

A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies

You may also be interested in...



BioShield House Compromise Could Serve As Template For Senate

The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate

BioShield House Compromise Could Serve As Template For Senate

The House Energy & Commerce Committee and White House funding compromise for Project BioShield could serve as a template for agreement in the Senate

PhRMA Urges Antitrust Exemption For Bioterrorism Research

An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says

Related Content

UsernamePublicRestriction

Register

PS041499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel